VPAS is dead, long live VPAG—could the UK’s new clawback revision save the day?
After months of intense negotiations, the UK Department of Social Care (DHSC) and the Association of the British Pharmaceutical Industry…
After months of intense negotiations, the UK Department of Social Care (DHSC) and the Association of the British Pharmaceutical Industry…
The punitive 2023 payback rate from the UK Government’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) has triggered…
The UK government’s decision to set an unprecedented payback rate of 26.5% on National Health Service (NHS) sales of branded…
As the Ukrainian population takes cover and entrenches its resistance to the Russian invasion, Ukraine's health minister Viktor Lyashko has…
In early May, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved a targeted anticancer drug, AstraZeneca's Tagrisso (osimertinib),…
While the UK has not yet seen a major cluster of infections in the current major international outbreak of coronavirus…
Within the next month, the US Food and Drug Administration (FDA) is set to review a landmark gene therapy product,…
It has taken a while, but at long last the UK government has issued its much-anticipated response to the Accelerated Access…
In a move which might best be described with the understatement "well, about time…", the UK's cross-parliamentary select committee on…
A recent survey, "Cost(less) Medicine", commissioned by the United States Agency for International Development (USAID) and conducted by the Patients…